Novel therapeutic targets in primary biliary cirrhosis

Jessica K. Dyson, Gideon M. Hirschfield, David H. Adams, Ulrich Beuers, Derek A. Mann, Keith Lindor, David E J Jones

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is a chronic immune-mediated liver disease characterized by progressive cholestasis, biliary fibrosis and eventually cirrhosis. It results in characteristic symptoms with marked effects on life quality. The advent of large patient cohorts has challenged the view of PBC as a benign condition treated effectively by the single licensed therapy-ursodeoxycholic acid (UDCA). UDCA nonresponse or under-response has a major bearing on outcome, substantially increasing the likelihood that liver transplantation will be required or that patients will die of the disease. In patients with high-risk, treatment-unresponsive or highly symptomatic disease the need for new treatment approaches is clear. Evolution in our understanding of disease mechanisms is rapidly leading to the advent of new and re-purposed therapeutic agents targeting key processes. Notable opportunities are offered by targeting what could be considered as the 'upstream' immune response, 'midstream' biliary injury and 'downstream' fibrotic processes. Combination therapy targeting several pathways or the development of novel agents addressing multiple components of the disease pathway might be required. Ultimately, PBC therapeutics will require a stratified approach to be adopted in practice. This Review provides a current perspective on potential approaches to PBC treatment, and highlights the challenges faced in evaluating and implementing those treatments.

Original languageEnglish (US)
Pages (from-to)147-158
Number of pages12
JournalNature Reviews Gastroenterology and Hepatology
Volume12
Issue number3
DOIs
StatePublished - Mar 6 2015

Fingerprint

Biliary Liver Cirrhosis
Ursodeoxycholic Acid
Therapeutics
Fibrosis
Cholestasis
Liver Transplantation
Liver Diseases
Quality of Life
Wounds and Injuries

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Dyson, J. K., Hirschfield, G. M., Adams, D. H., Beuers, U., Mann, D. A., Lindor, K., & Jones, D. E. J. (2015). Novel therapeutic targets in primary biliary cirrhosis. Nature Reviews Gastroenterology and Hepatology, 12(3), 147-158. https://doi.org/10.1038/nrgastro.2015.12

Novel therapeutic targets in primary biliary cirrhosis. / Dyson, Jessica K.; Hirschfield, Gideon M.; Adams, David H.; Beuers, Ulrich; Mann, Derek A.; Lindor, Keith; Jones, David E J.

In: Nature Reviews Gastroenterology and Hepatology, Vol. 12, No. 3, 06.03.2015, p. 147-158.

Research output: Contribution to journalArticle

Dyson, JK, Hirschfield, GM, Adams, DH, Beuers, U, Mann, DA, Lindor, K & Jones, DEJ 2015, 'Novel therapeutic targets in primary biliary cirrhosis', Nature Reviews Gastroenterology and Hepatology, vol. 12, no. 3, pp. 147-158. https://doi.org/10.1038/nrgastro.2015.12
Dyson, Jessica K. ; Hirschfield, Gideon M. ; Adams, David H. ; Beuers, Ulrich ; Mann, Derek A. ; Lindor, Keith ; Jones, David E J. / Novel therapeutic targets in primary biliary cirrhosis. In: Nature Reviews Gastroenterology and Hepatology. 2015 ; Vol. 12, No. 3. pp. 147-158.
@article{cf2572ae09d44ab3987ee8a4e008577e,
title = "Novel therapeutic targets in primary biliary cirrhosis",
abstract = "Primary biliary cirrhosis (PBC) is a chronic immune-mediated liver disease characterized by progressive cholestasis, biliary fibrosis and eventually cirrhosis. It results in characteristic symptoms with marked effects on life quality. The advent of large patient cohorts has challenged the view of PBC as a benign condition treated effectively by the single licensed therapy-ursodeoxycholic acid (UDCA). UDCA nonresponse or under-response has a major bearing on outcome, substantially increasing the likelihood that liver transplantation will be required or that patients will die of the disease. In patients with high-risk, treatment-unresponsive or highly symptomatic disease the need for new treatment approaches is clear. Evolution in our understanding of disease mechanisms is rapidly leading to the advent of new and re-purposed therapeutic agents targeting key processes. Notable opportunities are offered by targeting what could be considered as the 'upstream' immune response, 'midstream' biliary injury and 'downstream' fibrotic processes. Combination therapy targeting several pathways or the development of novel agents addressing multiple components of the disease pathway might be required. Ultimately, PBC therapeutics will require a stratified approach to be adopted in practice. This Review provides a current perspective on potential approaches to PBC treatment, and highlights the challenges faced in evaluating and implementing those treatments.",
author = "Dyson, {Jessica K.} and Hirschfield, {Gideon M.} and Adams, {David H.} and Ulrich Beuers and Mann, {Derek A.} and Keith Lindor and Jones, {David E J}",
year = "2015",
month = "3",
day = "6",
doi = "10.1038/nrgastro.2015.12",
language = "English (US)",
volume = "12",
pages = "147--158",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Novel therapeutic targets in primary biliary cirrhosis

AU - Dyson, Jessica K.

AU - Hirschfield, Gideon M.

AU - Adams, David H.

AU - Beuers, Ulrich

AU - Mann, Derek A.

AU - Lindor, Keith

AU - Jones, David E J

PY - 2015/3/6

Y1 - 2015/3/6

N2 - Primary biliary cirrhosis (PBC) is a chronic immune-mediated liver disease characterized by progressive cholestasis, biliary fibrosis and eventually cirrhosis. It results in characteristic symptoms with marked effects on life quality. The advent of large patient cohorts has challenged the view of PBC as a benign condition treated effectively by the single licensed therapy-ursodeoxycholic acid (UDCA). UDCA nonresponse or under-response has a major bearing on outcome, substantially increasing the likelihood that liver transplantation will be required or that patients will die of the disease. In patients with high-risk, treatment-unresponsive or highly symptomatic disease the need for new treatment approaches is clear. Evolution in our understanding of disease mechanisms is rapidly leading to the advent of new and re-purposed therapeutic agents targeting key processes. Notable opportunities are offered by targeting what could be considered as the 'upstream' immune response, 'midstream' biliary injury and 'downstream' fibrotic processes. Combination therapy targeting several pathways or the development of novel agents addressing multiple components of the disease pathway might be required. Ultimately, PBC therapeutics will require a stratified approach to be adopted in practice. This Review provides a current perspective on potential approaches to PBC treatment, and highlights the challenges faced in evaluating and implementing those treatments.

AB - Primary biliary cirrhosis (PBC) is a chronic immune-mediated liver disease characterized by progressive cholestasis, biliary fibrosis and eventually cirrhosis. It results in characteristic symptoms with marked effects on life quality. The advent of large patient cohorts has challenged the view of PBC as a benign condition treated effectively by the single licensed therapy-ursodeoxycholic acid (UDCA). UDCA nonresponse or under-response has a major bearing on outcome, substantially increasing the likelihood that liver transplantation will be required or that patients will die of the disease. In patients with high-risk, treatment-unresponsive or highly symptomatic disease the need for new treatment approaches is clear. Evolution in our understanding of disease mechanisms is rapidly leading to the advent of new and re-purposed therapeutic agents targeting key processes. Notable opportunities are offered by targeting what could be considered as the 'upstream' immune response, 'midstream' biliary injury and 'downstream' fibrotic processes. Combination therapy targeting several pathways or the development of novel agents addressing multiple components of the disease pathway might be required. Ultimately, PBC therapeutics will require a stratified approach to be adopted in practice. This Review provides a current perspective on potential approaches to PBC treatment, and highlights the challenges faced in evaluating and implementing those treatments.

UR - http://www.scopus.com/inward/record.url?scp=84924237361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924237361&partnerID=8YFLogxK

U2 - 10.1038/nrgastro.2015.12

DO - 10.1038/nrgastro.2015.12

M3 - Article

C2 - 25645973

AN - SCOPUS:84924237361

VL - 12

SP - 147

EP - 158

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

IS - 3

ER -